US Stock Insider Trading | Palvella disclosed 2 insider transactions on March 2

K-LinePoet · 2026-03-10T13:03:03+00:00

On March 2, 2026, Palvella disclosed insider trading, with Director Jenkins George M purchasing 4,000 shares on February 27. Recently, company executive Goin Kathleen also engaged in multiple stock transactions. Palvella is a biotechnology company founded in 2013, focused on developing drugs based on Anticalin proteins.

K-LinePoet

2026-03-10 13:03:03

Abstract generation in progress

On March 2, 2026, Palvella (PVLA) disclosed two insider trading transactions. Director JENKINS GEORGE M purchased 4,000 shares on February 27, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share (USD)	Total Amount (USD)
March 2, 2026	Director	HERON ELAINE J, JENKINS GEORGE M	February 27, 2026	Buy	6,400	125.00	$800,000
February 20, 2026	Executive	Goin Kathleen	February 18, 2026	Sell	1,276	79.97	$10,200
February 20, 2026	Executive	Goin Kathleen	February 18, 2026	Sell	3,026	79.16	$239,500
February 20, 2026	Executive	Goin Kathleen	February 18, 2026	Buy	2,148	9.08	$19,500
February 20, 2026	Executive	Goin Kathleen	February 18, 2026	Buy	2,154	7.14	$15,400
January 23, 2026	Executive	Goin Kathleen	January 21, 2026	Sell	3,749	97.94	$367,200
January 23, 2026	Executive	Goin Kathleen	January 21, 2026	Buy	2,154	7.14	$15,400
January 23, 2026	Executive	Goin Kathleen	January 21, 2026	Buy	2,148	9.08	$19,500
January 23, 2026	Executive	Goin Kathleen	January 21, 2026	Sell	553	95.49	$5,280
December 19, 2025	Executive	Goin Kathleen	December 17, 2025	Buy	2,154	7.14	$15,400

[Company Information]

Palvella Therapeutics, Inc. was incorporated under Nevada law on May 24, 2013. The company is a biotechnology firm that has historically discovered and developed drugs based on Anticalin proteins, targeting verified disease pathways in a unique and transformative manner. On March 27, 2024, the company implemented measures to maximize its ability to collect potential milestone payments from its collaborative clinical pipeline of drug candidates and to maintain the flexibility to consider other strategic options. The company’s clinical pipeline includes immuno-oncology or IO bispecific drugs developed in collaboration with partners, including S095012 (also known as PRS-344), targeting PD-L1 and 4-1BB; SGN-BB228 (also known as PRS-346), targeting CD228 and 4-1BB; and BOS-342 (also known as PRS-342), targeting GPC3 and 4-1BB. Anticalin proteins are proprietary to the company and represent a new class of therapeutics that have been validated in clinical trials through collaborations with leading pharmaceutical companies.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.